Inhibrx Biosciences, Inc. (INBX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $128.73: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate... Read more
Sell if holding. Engine safety override at $128.73: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 9.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $128.73: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $120.30. Score 4.3/10, moderate confidence.
Take-profit target: $255.00 (+97.1% upside). Prior stop was $120.30. Stop-loss: $120.30.
Quality below floor (2.3 < 4.0).
Inhibrx Biosciences, Inc. trades at a P/E of N/A (forward -44.7). TrendMatrix value score: 5.0/10. Verdict: Sell.
6 analysts cover INBX with a consensus score of 2.2/5. Average price target: $300.
What does Inhibrx Biosciences, Inc. do?Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic...
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.